Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2024-07-25 Earnings Release
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
Inside Information / Information on annual revenues
Earnings Release Classification · 100% confidence The document is explicitly titled "Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024" and provides detailed, unaudited financial highlights (sales figures, PPU volumes, unit sales) for Q2 and H1 2024. This content structure—announcing period-specific financial results before the comprehensive report is due—is characteristic of an Earnings Release (ER). It is not the full Annual Report (10-K) or the comprehensive Interim/Quarterly Report (IR), as it focuses on sales highlights and achievements rather than a full set of audited/comprehensive financial statements. The document also mentions the next financial release date, confirming its nature as a periodic results announcement. Q2 2024
2024-07-25 English
Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract
Regulatory Filings Classification · 95% confidence The document is a periodic disclosure of a liquidity contract, detailing share transactions (buy/sell side) and cash balances for Mauna Kea Technologies for the first half of 2024. This type of disclosure is a standard regulatory requirement for companies listed on European exchanges (like Euronext) to report on market-making activities. It does not fit the criteria for a full financial report (IR), earnings release (ER), or other specific categories, and is best classified as a regulatory filing. H1 2024
2024-07-17 English
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Capital/Financing Update Classification · 98% confidence The document is titled "BILAN SEMESTRIEL S1 2024 DU CONTRAT DE LIQUIDITÉ CONTRACTÉ AVEC LA SOCIÉTÉ DE BOURSE GILBERT DUPONT" (Half-Year Report S1 2024 of the Liquidity Contract with Gilbert Dupont Stock Brokerage). It details the activity (purchases and sales of shares, cash balance) related to a liquidity contract over the first semester (S1) of 2024, comparing it to the previous period (December 29, 2023). This document reports on the execution of a specific financial arrangement (liquidity contract/share buyback program) over a defined interim period (six months). This content is highly specific and relates to capital management/share transactions. While it involves shares, it is a report on the execution of a program, not a general capital change announcement (SHA) or a standard earnings report (ER/IR). It most closely aligns with the description of a report detailing the company's activity regarding its own shares, which points towards 'Transaction in Own Shares' (POS), as liquidity contracts are mechanisms for share repurchase/stabilization. Since it is a detailed report on the activity, it is classified as POS rather than a mere announcement (RPA).
2024-07-17 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information relative au nombre total de droits de vote et d'actions composant le capital social" (Information relative to the total number of voting rights and shares comprising the share capital) and explicitly references Article L233-8-II of the French Commercial Code and Article 223-16 of the AMF General Regulation. It provides a table detailing the number of shares outstanding and the total gross and net voting rights as of June 30, 2024. This type of mandatory periodic disclosure in France, detailing the total share capital and voting rights, is a specific regulatory filing. While it relates to capital structure, it is not a general financing announcement (CAP) or a share issue report (SHA). It is a specific regulatory disclosure regarding the capital base. Given the options, this specific disclosure about the total number of voting rights and shares is most closely related to notifications concerning major shareholdings or capital structure changes, but the core function here is reporting the total voting power, which often triggers thresholds. However, none of the codes perfectly match a 'Total Voting Rights Disclosure'. Since it is a mandatory regulatory disclosure concerning the capital structure and voting rights, and it is not a general earnings release, annual report, or management change, it falls under the category of specific regulatory reporting. In the context of the provided definitions, it is a specific regulatory announcement. If we must choose the closest fit among the provided codes: it is not a Director's Dealing (DIRS), not a Major Shareholding Notification (MRQ) which usually reports *changes* by an entity crossing a threshold, but rather a periodic statement of the total. Given the French regulatory context (AMF), this is a standard periodic disclosure. Since it is a specific regulatory filing that doesn't fit the other specific categories (like DIV, ER, 10-K), the most appropriate fallback for a specific, non-standard regulatory report is RNS, or potentially SHA if interpreted as a capital structure update. However, the content is purely about the count of shares and votes. Based on common classification schemes where periodic capital structure disclosures are often grouped, and lacking a specific 'Total Voting Rights' code, RNS (Regulatory Filings) serves as the best general regulatory disclosure category for this specific AMF requirement.
2024-07-04 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Monthly information regarding the total number of voting rights and shares comprising the share capital' and provides a table detailing the number of shares and voting rights as of June 30th, 2024. This type of regular disclosure concerning the total capital structure and voting rights is a specific regulatory requirement, often related to major shareholding notifications or general capital structure updates. Reviewing the definitions, this content most closely aligns with tracking changes in share ownership or capital structure. While 'Major Shareholding Notification' (MRQ) deals with crossing thresholds, this document is a mandatory monthly disclosure of the total count. Since it is a specific, recurring report on capital structure elements (shares and voting rights), it fits best under 'Share Issue/Capital Change' (SHA) or potentially 'Major Shareholding Notification' (MRQ) if interpreted broadly as related to ownership structure reporting. However, given the explicit focus on the total number of shares and voting rights, which is a fundamental aspect of capital structure reporting, SHA is a strong candidate. Alternatively, if this is a mandatory filing that doesn't fit elsewhere, RNS could be used. Given the specific nature of reporting total voting rights, which is often tied to capital changes or major ownership disclosures, and lacking a specific 'Voting Rights Disclosure' code, I will evaluate the closest fit. The document is a formal report providing specific figures on the capital base, not just an announcement of a transaction. It is not a general earnings release (ER) or an interim report (IR). Since it details the composition of the share capital, SHA (Share Issue/Capital Change) is the most appropriate category for reporting the current state of the share capital base, even if no *change* is announced in the text itself, as these reports are mandated by capital structure regulations. If this were a notification of a director's trade, it would be DIRS. If it were a notification of crossing a 5% threshold, it would be MRQ. Since it is the total count, SHA is the best fit among the provided options for capital structure reporting.
2024-07-04 English
Inside Information / Other news releases
Environmental & Social Information Classification · 99% confidence The document is a press release dated June 26, 2024, announcing the unveiling of a new subsidiary, CellTolerance, dedicated to food intolerance detection and treatment. It details new scientific data presented at Digestive Disease Week 2024, market opportunity, and strategic plans. This format—a formal announcement of significant business developments, clinical data, and strategic direction, issued by the company (Mauna Kea Technologies) via press release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full quarterly report (IR) or annual report (10-K), and it focuses on operational/strategic news rather than just financial results highlights (ER), it fits best as a general announcement. However, given the context of major business updates and strategic announcements that often accompany earnings cycles or significant corporate actions, and since it is not explicitly a proxy statement (DEF 14A) or a capital change notice (CAP/SHA), the most appropriate general category for a significant, non-standard regulatory announcement is Regulatory Filings (RNS). It is not a short announcement pointing to an attached report, so RPA is less likely than RNS for this substantive content.
2024-06-26 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.